Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Average Rating of “Moderate Buy” from Brokerages

Satellos Bioscience Inc. (NASDAQ:MSLE) has earned an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $19.75.

MSLE has been the subject of a number of research reports. Canaccord Genuity Group upgraded Satellos Bioscience to a “moderate buy” rating in a report on Thursday, May 21st. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. HC Wainwright lifted their price target on shares of Satellos Bioscience from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Guggenheim initiated coverage on shares of Satellos Bioscience in a research note on Tuesday, April 28th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Friday, August 7th.

Institutional Trading of Satellos Bioscience

A hedge fund recently raised its stake in Satellos Bioscience stock. AWM Investment Company Inc. boosted its stake in Satellos Bioscience Inc. (NASDAQ:MSLE) by 41.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 305,000 shares of the company’s stock after purchasing an additional 90,000 shares during the period. AWM Investment Company Inc. owned approximately 1.46% of Satellos Bioscience worth $2,338,000 at the end of the most recent reporting period.

Satellos Bioscience Stock Performance

MSLE stock opened at $9.61 on Friday. The firm’s 50-day moving average price is $8.21. Satellos Bioscience has a 12-month low of $4.84 and a 12-month high of $13.39. The stock has a market capitalization of $200.27 million, a P/E ratio of -5.00 and a beta of 1.51.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). Equities analysts predict that Satellos Bioscience will post -1.69 earnings per share for the current fiscal year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.